PMID- 31744855
OWN - NLM
STAT- MEDLINE
DCOM- 20201020
LR  - 20240229
IS  - 1535-9484 (Electronic)
IS  - 1535-9476 (Print)
IS  - 1535-9476 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Jan
TI  - The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune 
      Diseases.
PG  - 31-49
LID - S1535-9476(20)30004-9 [pii]
LID - 10.1074/mcp.R119.001743 [doi]
AB  - The science that investigates the ensembles of all peptides associated to human 
      leukocyte antigen (HLA) molecules is termed "immunopeptidomics" and is typically 
      driven by mass spectrometry (MS) technologies. Recent advances in MS 
      technologies, neoantigen discovery and cancer immunotherapy have catalyzed the 
      launch of the Human Immunopeptidome Project (HIPP) with the goal of providing a 
      complete map of the human immunopeptidome and making the technology so robust 
      that it will be available in every clinic. Here, we provide a long-term 
      perspective of the field and we use this framework to explore how we think the 
      completion of the HIPP will truly impact the society in the future. In this 
      context, we introduce the concept of immunopeptidome-wide association studies 
      (IWAS). We highlight the importance of large cohort studies for the future and 
      how applying quantitative immunopeptidomics at population scale may provide a new 
      look at individual predisposition to common immune diseases as well as 
      responsiveness to vaccines and immunotherapies. Through this vision, we aim to 
      provide a fresh view of the field to stimulate new discussions within the 
      community, and present what we see as the key challenges for the future for 
      unlocking the full potential of immunopeptidomics in this era of precision 
      medicine.
CI  - (c) 2020 Vizcaino et al.
FAU - Vizcaino, Juan Antonio
AU  - Vizcaino JA
AD  - European Molecular Biology Laboratory, European Bioinformatics Institute 
      (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, United 
      Kingdom.
FAU - Kubiniok, Peter
AU  - Kubiniok P
AD  - CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada.
FAU - Kovalchik, Kevin A
AU  - Kovalchik KA
AD  - CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada.
FAU - Ma, Qing
AU  - Ma Q
AD  - CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada; School of 
      Electrical Engineering and Computer Science, University of Ottawa, Ottawa, ON K1N 
      6N5, Canada.
FAU - Duquette, Jerome D
AU  - Duquette JD
AD  - CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada.
FAU - Mongrain, Ian
AU  - Mongrain I
AD  - Universite de Montreal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, QC, 
      Canada; Montreal Heart Institute, Montreal, QC, Canada.
FAU - Deutsch, Eric W
AU  - Deutsch EW
AD  - Institute for Systems Biology, Seattle, Washington, 98109.
FAU - Peters, Bjoern
AU  - Peters B
AD  - La Jolla Institute for Allergy and Immunology, La Jolla, California, 92037.
FAU - Sette, Alessandro
AU  - Sette A
AD  - La Jolla Institute for Allergy and Immunology, La Jolla, California, 92037.
FAU - Sirois, Isabelle
AU  - Sirois I
AD  - CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada.
FAU - Caron, Etienne
AU  - Caron E
AD  - CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada; Department of 
      Pathology and Cellular Biology, Faculty of Medicine, Universite de Montreal, QC 
      H3T 1J4, Canada. Electronic address: etienne.caron@umontreal.ca.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 208391/WT_/Wellcome Trust/United Kingdom
GR  - BB/P024599/1/BB_/Biotechnology and Biological Sciences Research Council/United 
      Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191119
PL  - United States
TA  - Mol Cell Proteomics
JT  - Molecular & cellular proteomics : MCP
JID - 101125647
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Peptides)
SB  - IM
MH  - Alleles
MH  - Autoimmune Diseases/*diagnosis/*therapy
MH  - Cohort Studies
MH  - HLA Antigens/*immunology
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Histocompatibility Antigens Class II/*immunology
MH  - Humans
MH  - Immunotherapy
MH  - Infections/diagnosis/therapy
MH  - Mass Spectrometry
MH  - Neoplasms/diagnosis/therapy
MH  - Peptides/*chemistry/*immunology
MH  - Precision Medicine
MH  - Prognosis
PMC - PMC6944237
OTO - NOTNLM
OT  - HLA/MHC
OT  - IWAS
OT  - Immunology
OT  - cancer therapeutics
OT  - immunopeptidome
OT  - infectious disease
OT  - mass spectrometry
OT  - peptides
COIS- The authors declare that they have no conflicts of interest with the contents of 
      this article.
EDAT- 2019/11/21 06:00
MHDA- 2020/10/21 06:00
PMCR- 2021/01/01
CRDT- 2019/11/21 06:00
PHST- 2019/08/23 00:00 [received]
PHST- 2019/11/18 00:00 [revised]
PHST- 2019/11/21 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/11/21 06:00 [entrez]
PHST- 2021/01/01 00:00 [pmc-release]
AID - S1535-9476(20)30004-9 [pii]
AID - R119.001743 [pii]
AID - 10.1074/mcp.R119.001743 [doi]
PST - ppublish
SO  - Mol Cell Proteomics. 2020 Jan;19(1):31-49. doi: 10.1074/mcp.R119.001743. Epub 
      2019 Nov 19.